Indian scientists identify synthetic compounds with potential to treat Alzheimer’s and Parkinson’s diseases

A team of Indian researchers has identified a class of compounds that could play a pivotal role in treating neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. This is reported by IANS, a partner of TV BRICS.

The study highlights the promise of peptidomimetics, synthetic molecules designed to imitate the behaviour and structure of natural proteins, in supporting neuronal growth, enhancing survival of nerve cells, and overcoming key limitations of current treatment approaches.

While neurotrophins, proteins essential for the development and survival of neurons, have long been considered potential therapeutic agents, their clinical application has been hindered by issues such as poor stability and rapid degradation.

These advantages make them strong candidates for drug development, especially for chronic neurodegenerative conditions where sustained therapeutic action is critical.

According to the researchers, peptidomimetics can be engineered to selectively bind to specific cellular receptors involved in neural signalling pathways, potentially reducing adverse effects and enhancing therapeutic precision. The compounds are also more resistant to enzymatic degradation, improving their longevity in the body compared to endogenous peptides.

The study further explores how these synthetic molecules may be repurposed for treating other diseases, including certain forms of cancer, and supports the development of next-generation neurotherapeutics based on neurotrophin-inspired designs.

Photo: iStock